HEALTH

Study reveals that exercise during pregnancy aids fetal development

BY Michael Johnsen

NEW ORLEANS According to a study called the “Effects of Maternal Exercise on Fetal Breathing Movements,” researchers determined that exercise during pregnancy may benefit fetal development.

Specifically, fetal heart rate was significantly lower in a control exercise group during both breathing and non-breathing movement periods; and fetal short-term and overall heart rate variability were higher in the exercise group during breathing movements.

“These findings suggest a potential benefit of maternal exercise on fetal development because of the link between fetal breathing movements and the developing autonomic nervous system,” stated Linda May of the Kansas City University of Medicine and Biosciences.

The researchers are planning to next explore the use exercise as a potential intervention to improve short and long term outcomes in children born to women at risk for gestational diabetes.

The researchers will discuss their findings at the 122nd Annual Meeting of the American Physiological Society, which is part of the Experimental Biology 2009 scientific conference in New Orleans April 18 through 22.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

Nuvilex reduces suggested list price of Cinnergen

BY Michael Johnsen

CHERRY HILL, N.J. Nuvilex, formerly eFoodSafety.com, last week reduced the suggested list price of Cinnergen, a cranberry cinnamon liquid supplement, corresponding with an advertising and promotion campaign that helps promote healthy glucose metabolism, raise customer awareness and garner increased demand for the product at the lower price point.

“By improving our marketing and sales efforts, we intend to raise awareness and drive demand for Cinnergen,” stated Martin Schmieg, Nuvilex chairman and CEO. “Engaging our retail partners with better pricing while maintaining current gross margin levels will help us in retail positioning, and the lower suggested retail price will be good for current and future Cinnergen users. Furthermore, our partnership with dLife will expose Cinnergen to the large pre-diabetic and diabetic population that is looking for healthy alternatives. We plan to closely monitor and track our Cinnergen advertising and promotion activities and hope to report a significant return on our investment.”

Nuvilex has executed a partnership agreement for the promotion of Cinnergen with dLife, the only multimedia network serving the diabetes community. The dLife advertising and promotion campaign is expected to launch in mid-April. The multimedia outlets include dLife TV, which airs every Sunday on CNBC at 7 p.m. With more than 80,000 pages of content, 9,000 diabetic recipes, and 400 videos, dLife.com is a leading online destination for diabetes information. The dLife network also includes: dLifeRadio, which can be heard on stations around the country and on XM Satellite Radio; and dLifeDirect, the only diabetes cooperative direct-mail program.

Phase one of the dLife partnership will include 1.2 million banner ads plus content integration on the dLife website, banner advertising in three upcoming dLife newsletters (350,000 circulation) and banner advertising in the upcoming Rite Aid Connect Newsletter (550,000 circulation). Nuvilex has engaged the Iridium Group to design its web and print placement ads and will also focus on improving its search positions with Google and Yahoo. Nuvilex also intends to promote Cinnergen on WebMD.

Effective May 1, Nuvilex will reduce the suggested retail price for a 32-ounce bottle of Cinnergen to $26.95 from $34.95. Additionally, lower multi-level wholesale pricing will be established to support the Company’s retail partners.

Nuvilex will discontinue production of the 16-ounce bottle size of Cinnergen.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

Stem cells may curb insulin use for Type 1 diabetes patients, study finds

BY Alaric DeArment

NEW YORK An experimental stem-cell treatment for juvenile-onset diabetes kept patients off insulin for at least a year, according to published reports.

According to WebMD, of patients recently diagnosed with Type 1 diabetes who received the treatment, more than half were able to go without insulin for at least a year, and four patients managed to go without it for at least three years. The treatment also uses drugs to suppress the immune system, however, and two of the patients contracted pneumonia.

The original study appears in the April 15 issue of the Journal of the American Medical Association.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?